Disclosed are chromane compounds, analogs thereof, and methods of their synthesis and use. The compounds may be synthesized by methods involving reductive annulations of arylidene malonates with unsaturated electrophiles using photoredox/Lewis acid cooperative catalysis. The compounds may be formulated in a pharmaceutical composition for treating one of the aforementioned diseases or disorders.

Disclosed are chromane compounds, analogs thereof, and methods of their synthesis and use. The compounds may be synthesized by methods involving reductive annulations of arylidene malonates with unsaturated electrophiles using photoredox/Lewis acid cooperative catalysis. The compounds may be formulated in a pharmaceutical composition for treating one of the aforementioned diseases or disorders.

Disclosed are chromane compounds, analogs thereof, and methods of their synthesis and use. The compounds may be synthesized by methods involving reductive annulations of arylidene malonates with unsaturated electrophiles using photoredox/Lewis acid cooperative catalysis. The compounds may be formulated in a pharmaceutical composition for treating one of the aforementioned diseases or disorders.

Disclosed are chromane compounds, analogs thereof, and methods of their synthesis and use. The compounds may be synthesized by methods involving reductive annulations of arylidene malonates with unsaturated electrophiles using photoredox/Lewis acid cooperative catalysis. The compounds may be formulated in a pharmaceutical composition for treating one of the aforementioned diseases or disorders.

An organic electroluminescence device comprising: a cathode, an anode, and an organic layer disposed between the cathode and the anode, wherein the organic layer comprises a compound represented by the following formula (1), and a compound A having a Stokes shift of 20 nm or smaller and an emission peak wavelength of 440 nm to 465 nm (at least one of Ar.sub.1 and Ar.sub.2 is a monovalent group having a structure represented by the following formula (2)).

##STR00001##

A compound represented by the following formula (1), wherein in the formula, L.sub.1 and L.sub.2 are predetermined linking groups, and Ar.sub.1 is a monovalent group having a structure represented by the following formula (2).

##STR00001##

A process for preparing coumarin-caged forskolin derivatives, the forskolin derivatives themselves and to uses of the same.

A process for preparing coumarin-caged forskolin derivatives, the forskolin derivatives themselves and to uses of the same.

The present disclosure is drawn to methods of treating diseases or disorders, and uses of preparing medicaments. The methods of administering and/or preparation of medicaments can include the use of a compound of Formula (I) disclosed herein, or a geometric isomer, stereoisomer, and/or pharmaceutically acceptable salt or solvate thereof.

Provided are a drug, a pharmaceutical composition, or a pharmaceutical kit for immunosuppression, for the treatment of conditions such as psoriasis, comprising a forskolin derivative or a salt thereof and optionally a prostaglandin compound or a glucocorticoid compound. Further provided is a method for immunosuppression, comprising administration of a forskolin derivative or a salt thereof and optionally a prostaglandin compound or a glucocorticoid compound. Forskolin derivatives show promise as a class of small-molecule drugs for achieving immunosuppression using new mechanisms, for the treatment of conditions such as psoriasis, when used alone or in combination with other substances. Compared with first-line antibody drugs, forskolin derivatives have significant advantages in process and price, and have comparable efficacy and fewer side effects compared with the first-line drug calcipotriol betamethasone ointment.